[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-liver-damage-myths-de":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"cat":9,"icon":10,"accent":11,"date":12,"dateLabel":13,"read":14,"author":15,"image":16,"body":17,"_type":2434,"_id":2435,"_source":2436,"_file":2437,"_stem":2438,"_extension":2439},"\u002Fblog\u002Fde\u002Fretatrutide-liver-damage-myths","de",false,"","Retatrutid und die Leber: der Faktencheck","Faktencheck","tabler:microscope","#F2A93B","2026-06-27","Juni 2026","20 Min.","myPeptides Team","\u002Fassets\u002Freta_hero.png",{"type":18,"children":19,"toc":2412},"root",[20,124,131,143,318,323,329,335,340,349,400,419,425,463,481,487,492,500,536,562,568,573,581,601,666,672,677,685,732,738,743,786,792,797,802,806,812,817,823,843,871,877,898,933,939,972,1012,1018,1070,1091,1127,1145,1238,1255,1347,1352,1358,1377,1423,1429,1441,1468,1474,1506,1512,1526,1532,1569,1596,1602],{"type":21,"tag":22,"props":23,"children":24},"element","disclaimer",{},[25,38,70,80,99,116],{"type":21,"tag":26,"props":27,"children":28},"p",{},[29,36],{"type":21,"tag":30,"props":31,"children":32},"em",{},[33],{"type":34,"value":35},"text","Das hier ist Meinung und wissenschaftlicher Kommentar — keine medizinische Beratung und keine Tatsachenbehauptung über irgendeine Person, die über das Belegte hinausginge.",{"type":34,"value":37}," Dieser Artikel setzt sich im öffentlichen Interesse und als faire Stellungnahme mit medizinischen Behauptungen auseinander, die eine Person des öffentlichen Lebens bewusst und vor großem Publikum verbreitet hat.",{"type":21,"tag":26,"props":39,"children":40},{},[41,47,49,54,56,61,63,68],{"type":21,"tag":42,"props":43,"children":44},"strong",{},[45],{"type":34,"value":46},"Tatsachen vs. Meinung.",{"type":34,"value":48}," Wo wir überprüfbare Tatsachen nennen — den berufsrechtlichen Zulassungsstatus, Geschäftsbeteiligungen, den Wortlaut öffentlich verfügbarer Dokumente und Videos — verlinken wir die Primärquellen, damit du es selbst nachprüfen kannst. Alles, was wir als ",{"type":21,"tag":30,"props":50,"children":51},{},[52],{"type":34,"value":53},"Einschätzung",{"type":34,"value":55},", als ",{"type":21,"tag":30,"props":57,"children":58},{},[59],{"type":34,"value":60},"Lesart der Daten",{"type":34,"value":62}," oder als unsere ",{"type":21,"tag":30,"props":64,"children":65},{},[66],{"type":34,"value":67},"Auffassung",{"type":34,"value":69}," kennzeichnen, ist Meinung und faire Stellungnahme zu öffentlich getätigten Aussagen. Wir behaupten nicht, die privaten Absichten irgendeiner Person zu kennen; wo wir Motiv oder Wirkung beschreiben, beschreiben wir sie so, wie wir sie sehen — nicht als erwiesene Tatsache.",{"type":21,"tag":26,"props":71,"children":72},{},[73,78],{"type":21,"tag":42,"props":74,"children":75},{},[76],{"type":34,"value":77},"Quellen können lückenhaft sein.",{"type":34,"value":79}," Alle Angaben hier stammen aus öffentlich zugänglichen Quellen und sind nach bestem Wissen und Gewissen und in gutem Glauben zum Zeitpunkt des Schreibens wiedergegeben. Öffentliche Dokumente und Berichte Dritter können unvollständig sein, sich ändern oder überholt sein; uns kann Kontext entgangen sein, und wir können uns in Details irren.",{"type":21,"tag":26,"props":81,"children":82},{},[83,88,90,97],{"type":21,"tag":42,"props":84,"children":85},{},[86],{"type":34,"value":87},"Gegendarstellung und Korrektur.",{"type":34,"value":89}," Falls du hier erwähnt wirst und eine Tatsachenbehauptung für falsch oder veraltet hältst — oder deine Sicht ergänzen möchtest — melde dich über unser ",{"type":21,"tag":91,"props":92,"children":94},"a",{"href":93},"\u002Flegal-notice",[95],{"type":34,"value":96},"Impressum",{"type":34,"value":98},"; wir sehen uns den Artikel an und korrigieren oder aktualisieren ihn, wo es geboten ist. Belegte Korrekturen sind jederzeit willkommen.",{"type":21,"tag":26,"props":100,"children":101},{},[102,107,109,114],{"type":21,"tag":42,"props":103,"children":104},{},[105],{"type":34,"value":106},"Keine medizinische Beratung — und keine Aufforderung, irgendetwas anzuwenden.",{"type":34,"value":108}," Nichts hier sagt dir, was du mit deinem eigenen Körper tun sollst, und nichts hier empfiehlt dir oder fordert dich auf, Retatrutid oder irgendeine andere Substanz zu beschaffen, zu dosieren oder anzuwenden — einige davon sind Prüfsubstanzen und an vielen Orten nicht für die Anwendung am Menschen zugelassen. Die Studienzahlen, die wir zitieren, beschreiben Ergebnisse aus veröffentlichten Studien; sie sind keine Zusage irgendeines Resultats und keine Dosierungsanleitung. Wenn du erwägst, eine dieser Substanzen anzuwenden, oder sie bereits anwendest, dann ",{"type":21,"tag":42,"props":110,"children":111},{},[112],{"type":34,"value":113},"geh zu dem Arzt, dem du am wenigsten misstraust — persönlich —",{"type":34,"value":115},", bevor du auf irgendetwas reagierst, das du online liest, hier oder anderswo.",{"type":21,"tag":26,"props":117,"children":118},{},[119],{"type":21,"tag":30,"props":120,"children":121},{},[122],{"type":34,"value":123},"Zuletzt aktualisiert: 27. Juni 2026. Dieser Artikel ist Meinung und Kommentar und kann überarbeitet werden, sobald neue Informationen vorliegen.",{"type":21,"tag":125,"props":126,"children":128},"h2",{"id":127},"tldr",[129],{"type":34,"value":130},"TL;DR",{"type":21,"tag":26,"props":132,"children":133},{},[134,136,141],{"type":34,"value":135},"Ein 45-minütiges Video mit dem Titel ",{"type":21,"tag":30,"props":137,"children":138},{},[139],{"type":34,"value":140},"„Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":34,"value":142}," behauptet, Retatrutid schädige still und leise Leber und Bauchspeicheldrüse — es sei denn, du hältst dich an ein ganz bestimmtes Dosierungsprotokoll, das der Vortragende dann prompt verkauft, zusammen mit den Peptiden selbst. Wir haben es überprüft. Die Kurzfassung:",{"type":21,"tag":144,"props":145,"children":146},"ul",{},[147,184,234,259,299],{"type":21,"tag":148,"props":149,"children":150},"li",{},[151,156,158,163,165,173,175,182],{"type":21,"tag":42,"props":152,"children":153},{},[154],{"type":34,"value":155},"Der Überbringer.",{"type":34,"value":157}," „Dr\" Trevor Bachmeyer ist kein Arzt. Er ist ein ehemaliger Chiropraktiker, dessen kalifornische Zulassung (DC 29377) ",{"type":21,"tag":42,"props":159,"children":160},{},[161],{"type":34,"value":162},"mit Wirkung zum 8. Juli 2020 widerrufen wurde",{"type":34,"value":164},", dokumentiert vom ",{"type":21,"tag":91,"props":166,"children":170},{"href":167,"rel":168},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[169],"nofollow",[171],{"type":34,"value":172},"California Board of Chiropractic Examiners",{"type":34,"value":174},". Dasselbe Video schickt seine Zuschauer weiter zu seinem kostenpflichtigen Coaching und zu seinem eigenen Research-Peptid-Shop ",{"type":21,"tag":91,"props":176,"children":179},{"href":177,"rel":178},"https:\u002F\u002Felitebiogenix.com\u002F",[169],[180],{"type":34,"value":181},"EliteBiogenix",{"type":34,"value":183},".",{"type":21,"tag":148,"props":185,"children":186},{},[187,192,194,199,201,206,208,215,217,224,225,232],{"type":21,"tag":42,"props":188,"children":189},{},[190],{"type":34,"value":191},"„Glukagon überflutet deinen Körper mit Fett.\"",{"type":34,"value":193}," Irreführend. Beim Menschen baut körpereigenes Glukagon Körperfett (weißes Fettgewebe) ",{"type":21,"tag":42,"props":195,"children":196},{},[197],{"type":34,"value":198},"nicht",{"type":34,"value":200}," direkt ab — es kurbelt die Fettverbrennung ",{"type":21,"tag":30,"props":202,"children":203},{},[204],{"type":34,"value":205},"in der Leber",{"type":34,"value":207}," an (",{"type":21,"tag":91,"props":209,"children":212},{"href":210,"rel":211},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[169],[213],{"type":34,"value":214},"Perry et al., Nature 2020",{"type":34,"value":216},"; ",{"type":21,"tag":91,"props":218,"children":221},{"href":219,"rel":220},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[169],[222],{"type":34,"value":223},"Vasileva et al., 2022",{"type":34,"value":216},{"type":21,"tag":91,"props":226,"children":229},{"href":227,"rel":228},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[169],[230],{"type":34,"value":231},"Gravholt et al., 2001",{"type":34,"value":233},").",{"type":21,"tag":148,"props":235,"children":236},{},[237,242,244,249,251,258],{"type":21,"tag":42,"props":238,"children":239},{},[240],{"type":34,"value":241},"„Steigende Lipase heißt, deine Bauchspeicheldrüse macht schlapp.\"",{"type":34,"value":243}," Größtenteils falsch. Milde, beschwerdefreie Enzymanstiege sind häufig und harmlos; große Studiendatensätze zeigen ",{"type":21,"tag":42,"props":245,"children":246},{},[247],{"type":34,"value":248},"keinen Anstieg akuter Pankreatitiden",{"type":34,"value":250}," (",{"type":21,"tag":91,"props":252,"children":255},{"href":253,"rel":254},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[169],[256],{"type":34,"value":257},"Steinberg et al., Diabetes Care 2017",{"type":34,"value":233},{"type":21,"tag":148,"props":260,"children":261},{},[262,267,269,274,276,281,283,290,292,297],{"type":21,"tag":42,"props":263,"children":264},{},[265],{"type":34,"value":266},"„Retatrutid überlastet und schädigt die Leber.\"",{"type":34,"value":268}," Das genaue Gegenteil der Daten. In der Phase-2-Leberfett-Studie ",{"type":21,"tag":42,"props":270,"children":271},{},[272],{"type":34,"value":273},"senkte es das Leberfett um bis zu 86 %",{"type":34,"value":275},", und ",{"type":21,"tag":42,"props":277,"children":278},{},[279],{"type":34,"value":280},"rund 93 % der Patienten unter der Höchstdosis normalisierten",{"type":34,"value":282}," ihr Leberfett (",{"type":21,"tag":91,"props":284,"children":287},{"href":285,"rel":286},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[169],[288],{"type":34,"value":289},"Sanyal et al., Nature Medicine 2024",{"type":34,"value":291},"). Retatrutid wird ",{"type":21,"tag":30,"props":293,"children":294},{},[295],{"type":34,"value":296},"als Therapie",{"type":34,"value":298}," gegen die Fettleber entwickelt.",{"type":21,"tag":148,"props":300,"children":301},{},[302,307,309,316],{"type":21,"tag":42,"props":303,"children":304},{},[305],{"type":34,"value":306},"Was er richtig sieht.",{"type":34,"value":308}," Zwei Dinge: Setz das Medikament nicht panisch wegen eines einzelnen Lipase-Werts ab, und schneller Gewichtsverlust kostet tatsächlich Muskulatur (",{"type":21,"tag":91,"props":310,"children":313},{"href":311,"rel":312},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[169],[314],{"type":34,"value":315},"Koceva et al., 2025",{"type":34,"value":317},"). Stichhaltige Punkte, verpackt in eine unhaltbare Panikmache.",{"type":21,"tag":26,"props":319,"children":320},{},[321],{"type":34,"value":322},"Das vollständigere Bild und die Wissenschaft hinter jeder dieser Zeilen kommen gleich. Der ausführliche Teil am Ende ist eine mit Quellen unterlegte Einführung in die gesamte Wirkstoffklasse — so geschrieben, dass du uns überprüfen kannst und uns nicht einfach glauben musst.",{"type":21,"tag":324,"props":325,"children":328},"youtube",{"id":326,"title":327},"gb-XEtsMr-w","Das Video, das dieser Artikel untersucht — Bachmeyer über die Dosierung von Retatrutid",[],{"type":21,"tag":125,"props":330,"children":332},{"id":331},"wer-die-behauptung-aufstellt",[333],{"type":34,"value":334},"Wer die Behauptung aufstellt",{"type":21,"tag":26,"props":336,"children":337},{},[338],{"type":34,"value":339},"Vor der Wissenschaft kommt die Quelle. Vor einem Publikum von Hunderttausenden vermarktet er sich als „Dr Trevor Bachmeyer, The Spartan\" und „World's #1 Health Authority\". Zwei überprüfbare Tatsachen sind hier entscheidend.",{"type":21,"tag":26,"props":341,"children":342},{},[343],{"type":21,"tag":344,"props":345,"children":348},"img",{"alt":346,"src":347},"Wie sich eine Gesundheitsangst gezielt in einen Produktverkauf umlenken lässt","\u002Fassets\u002Freta_funnel.png",[],{"type":21,"tag":26,"props":350,"children":351},{},[352,354,359,361,366,368,373,375,381,382,389,391,398],{"type":34,"value":353},"Erstens: ",{"type":21,"tag":42,"props":355,"children":356},{},[357],{"type":34,"value":358},"Er ist kein Arzt.",{"type":34,"value":360}," Er ist ein ehemaliger ",{"type":21,"tag":42,"props":362,"children":363},{},[364],{"type":34,"value":365},"Chiropraktiker",{"type":34,"value":367},", und selbst diese Zulassung ist weg: Die kalifornische Lizenz DC 29377 wurde vom California Board of Chiropractic Examiners ",{"type":21,"tag":42,"props":369,"children":370},{},[371],{"type":34,"value":372},"mit Wirkung zum 8. Juli 2020 widerrufen",{"type":34,"value":374},". Die Maßnahme ist in den eigenen Unterlagen des Board dokumentiert (",{"type":21,"tag":91,"props":376,"children":378},{"href":167,"rel":377},[169],[379],{"type":34,"value":380},"Sitzungsmaterialien, 29. Okt. 2020",{"type":34,"value":216},{"type":21,"tag":91,"props":383,"children":386},{"href":384,"rel":385},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[169],[387],{"type":34,"value":388},"Final Disciplinary Actions",{"type":34,"value":390},") und über die staatliche ",{"type":21,"tag":91,"props":392,"children":395},{"href":393,"rel":394},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[169],[396],{"type":34,"value":397},"Lizenzabfrage",{"type":34,"value":399}," nachprüfbar — die genauen Feststellungen kannst du in den verlinkten Unterlagen nachlesen. Trotzdem tritt er weiter als „Dr\" auf — eine Verwendung, die aus unserer Sicht die Leute glauben lässt, er habe eine aktuelle ärztliche Qualifikation, die er in Wahrheit nicht besitzt.",{"type":21,"tag":26,"props":401,"children":402},{},[403,405,410,412,417],{"type":34,"value":404},"Zweitens: ",{"type":21,"tag":42,"props":406,"children":407},{},[408],{"type":34,"value":409},"Er verkauft genau das, wozu er rät.",{"type":34,"value":411}," Das Video leitet die Zuschauer zu einer kostenpflichtigen „Black Card\"-Coaching-Mitgliedschaft und zu ",{"type":21,"tag":91,"props":413,"children":415},{"href":177,"rel":414},[169],[416],{"type":34,"value":181},{"type":34,"value":418}," weiter, seinem Shop, der Research-Peptide und SARMs „nur zur In-vitro-Forschung\" verkauft. Die Person also, die dich warnt, Retatrutid werde dir schaden, wenn du es nicht korrekt dosierst, verkauft dir zugleich die Dosierungsanleitung und die Peptide dazu. Das allein ist kein Ausschlussgrund — aber es ist genau der Interessenkonflikt, den ein aufmerksamer Zuschauer im Hinterkopf behalten sollte, und der Grund, warum es diesen Artikel gibt.",{"type":21,"tag":125,"props":420,"children":422},{"id":421},"was-er-tatsächlich-vorbringt-der-fairness-halber",[423],{"type":34,"value":424},"Was er tatsächlich vorbringt — der Fairness halber",{"type":21,"tag":26,"props":426,"children":427},{},[428,430,435,437,442,444,449,451,456,458],{"type":34,"value":429},"Es wäre leicht, ihm einen Strohmann unterzuschieben, also bleiben wir genau. Seine eigene Videobeschreibung sagt, dass ",{"type":21,"tag":30,"props":431,"children":432},{},[433],{"type":34,"value":434},"„retatrutide itself doesn't directly cause liver or pancreatic damage; irresponsible dosing and poor monitoring causes biological damage.\"",{"type":34,"value":436}," Seine Kapitelliste lautet ",{"type":21,"tag":30,"props":438,"children":439},{},[440],{"type":34,"value":441},"„Glucagon Fat Flood → Pancreas Overload → Fatty Liver Cascade → Insulin Resistance Spiral,\"",{"type":34,"value":443}," und schwenkt dann zu einem ",{"type":21,"tag":30,"props":445,"children":446},{},[447],{"type":34,"value":448},"„Damage Control Protocol,\"",{"type":34,"value":450}," ",{"type":21,"tag":30,"props":452,"children":453},{},[454],{"type":34,"value":455},"„Safe Dosing Rules,\"",{"type":34,"value":457}," und ",{"type":21,"tag":30,"props":459,"children":460},{},[461],{"type":34,"value":462},"„Use It Responsibly.\"",{"type":21,"tag":26,"props":464,"children":465},{},[466,468,472,474,479],{"type":34,"value":467},"Seine These ist also ",{"type":21,"tag":42,"props":469,"children":470},{},[471],{"type":34,"value":198},{"type":34,"value":473}," „dieses Medikament ist Gift, Finger weg\". Sie lautet „dieses Medikament schädigt dich, ",{"type":21,"tag":30,"props":475,"children":476},{},[477],{"type":34,"value":478},"wenn du es nicht so dosierst, wie ich es sage",{"type":34,"value":480},"\". Das ist subtiler, klingt glaubwürdiger und lässt sich deutlich besser verkaufen — und genau das prüfen wir. Das Problem ist nicht, dass er Studien fälscht. Es ist, dass er aus echten Fachbegriffen einen furchteinflößenden Mechanismus zusammenbaut — und die Studiendaten den furchteinflößenden Teil nicht hergeben.",{"type":21,"tag":125,"props":482,"children":484},{"id":483},"behauptung-1-die-glukagon-fettflut",[485],{"type":34,"value":486},"Behauptung 1: die „Glukagon-Fettflut\"",{"type":21,"tag":26,"props":488,"children":489},{},[490],{"type":34,"value":491},"Sein Motor ist die Glukagon-Komponente von Retatrutid: Sie entfessle eine Fettflut — freie Fettsäuren, die aus dem Körperfett strömen und Leber wie Bauchspeicheldrüse überrollen.",{"type":21,"tag":26,"props":493,"children":494},{},[495],{"type":21,"tag":344,"props":496,"children":499},{"alt":497,"src":498},"Glukagon treibt die Fettverbrennung in der Leber an, nicht im Körperfett","\u002Fassets\u002Freta_glucagon.png",[],{"type":21,"tag":26,"props":501,"children":502},{},[503,505,510,512,518,520,526,527,534],{"type":34,"value":504},"Das ist der älteste Mythos der Glukagon-Physiologie. Ja, Glukagon ist ein starkes Signal zur Fettverbrennung — ",{"type":21,"tag":42,"props":506,"children":507},{},[508],{"type":34,"value":509},"aber in der Leber, nicht in deinem Körperfett.",{"type":34,"value":511}," Der Glukagonrezeptor sitzt dicht an dicht auf den Leberzellen und ist auf menschlichen Fettzellen kaum vorhanden. Als Forscher den Glukagonrezeptor gezielt aus dem Fettgewebe von Mäusen entfernten, änderte sich an deren Fettstoffwechsel, Körpergewicht und zirkulierenden freien Fettsäuren nichts (",{"type":21,"tag":91,"props":513,"children":515},{"href":219,"rel":514},[169],[516],{"type":34,"value":517},"Vasileva et al., AJP-Endocrinology 2022",{"type":34,"value":519},"). Und beim Menschen bringt es die Lipolyse im Bauchfett kein bisschen in Gang, wenn man Glukagon auf physiologische Werte anhebt (",{"type":21,"tag":91,"props":521,"children":523},{"href":227,"rel":522},[169],[524],{"type":34,"value":525},"Gravholt et al., JCEM 2001",{"type":34,"value":216},{"type":21,"tag":91,"props":528,"children":531},{"href":529,"rel":530},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[169],[532],{"type":34,"value":533},"Jensen et al., JCEM 1991",{"type":34,"value":535},"). Der fettlösende Effekt zeigt sich nur im Reagenzglas, bei supraphysiologischen Konzentrationen, die der Blutkreislauf nie erreicht.",{"type":21,"tag":26,"props":537,"children":538},{},[539,541,545,547,552,553,560],{"type":34,"value":540},"Was Glukagon wirklich tut, ist, die Fettoxidation ",{"type":21,"tag":42,"props":542,"children":543},{},[544],{"type":34,"value":205},{"type":34,"value":546}," anzutreiben — über einen cAMP\u002FPKA- und Calcium-Signalweg, der den Fettabbau in der Leber aktiviert (",{"type":21,"tag":91,"props":548,"children":550},{"href":210,"rel":549},[169],[551],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":554,"children":557},{"href":555,"rel":556},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[169],[558],{"type":34,"value":559},"Kajani et al., Physiological Reviews 2024",{"type":34,"value":561},") — und den Gesamtenergieumsatz zu erhöhen. Das Bild von einem Glukagon, das dein Bauchfett „schmelzen\" lässt und deine Organe damit überschwemmt, ist ein Reagenzglas-Artefakt, keine menschliche Physiologie. Das Fundament seiner „Flut\" bekommt schon im ersten Kapitel Risse.",{"type":21,"tag":125,"props":563,"children":565},{"id":564},"behauptung-2-die-pankreas-überlastung",[566],{"type":34,"value":567},"Behauptung 2: die Pankreas-„Überlastung\"",{"type":21,"tag":26,"props":569,"children":570},{},[571],{"type":34,"value":572},"Als Nächstes die erhöhte Lipase — angeblich der Beweis, dass die Bauchspeicheldrüse auf ein Versagen zusteuert.",{"type":21,"tag":26,"props":574,"children":575},{},[576],{"type":21,"tag":344,"props":577,"children":580},{"alt":578,"src":579},"Ein milder Lipase-Anstieg ist ein harmloses Enzymleck, keine Zerstörung der Bauchspeicheldrüse","\u002Fassets\u002Freta_pancreas.png",[],{"type":21,"tag":26,"props":582,"children":583},{},[584,586,591,593,600],{"type":34,"value":585},"Die unspektakuläre Realität: Milde, beschwerdefreie Anstiege von Lipase und Amylase sind bei dieser Wirkstoffklasse ",{"type":21,"tag":42,"props":587,"children":588},{},[589],{"type":34,"value":590},"häufig und meist harmlos.",{"type":34,"value":592}," Sie spiegeln stimulierte, aber intakte Azinuszellen wider, die etwas Enzym ins Blut abgeben — ein physiologisches „Leck\", keine sich selbst verdauende Bauchspeicheldrüse. Wir kennen sogar den Rezeptormechanismus dahinter: GLP-1-Rezeptoren sitzen auf den Azinuszellen der Bauchspeicheldrüse und regen sie an, Enzym freizusetzen — in gesundem Gewebe und ohne Schaden (",{"type":21,"tag":91,"props":594,"children":597},{"href":595,"rel":596},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[169],[598],{"type":34,"value":599},"Hou… Williams et al., AJP-GI 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":602,"children":603},{},[604,606,611,612,617,619,626,628,633,635,642,644,649,651,655,657,664],{"type":34,"value":605},"Und die harten Endpunkte sind beruhigend. In den großen Liraglutid-Studienprogrammen stiegen Amylase und Lipase moderat an, ",{"type":21,"tag":42,"props":607,"children":608},{},[609],{"type":34,"value":610},"ohne dass daraus eine akute Pankreatitis folgte",{"type":34,"value":250},{"type":21,"tag":91,"props":613,"children":615},{"href":253,"rel":614},[169],[616],{"type":34,"value":257},{"type":34,"value":618},"). Ein lebendes systematisches Review von 2026, das 31 placebokontrollierte Studien und über 40.000 Patienten zusammenfasst, fand praktisch identische Pankreatitis-Raten unter Wirkstoff und Placebo (Odds Ratio ≈ 0,99) — wobei dieses, der Fairness halber, noch ein ",{"type":21,"tag":91,"props":620,"children":623},{"href":621,"rel":622},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[169],[624],{"type":34,"value":625},"Preprint",{"type":34,"value":627}," und nicht peer-reviewt ist. Eine Analyse von 2024 berichtete sogar ",{"type":21,"tag":42,"props":629,"children":630},{},[631],{"type":34,"value":632},"weniger",{"type":34,"value":634}," wiederkehrende Pankreatitis-Schübe bei Hochrisikopatienten unter GLP-1-Medikamenten (",{"type":21,"tag":91,"props":636,"children":639},{"href":637,"rel":638},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[169],[640],{"type":34,"value":641},"Nassar et al., ENDO 2024 — Kongressabstract",{"type":34,"value":643},"), vermutlich, weil die Medikamente die eigentlichen Auslöser mitbehandeln. Entscheidend: Die akute Pankreatitis ist eine klinische Diagnose — die überarbeiteten Atlanta-Kriterien verlangen echte Schmerzen ",{"type":21,"tag":30,"props":645,"children":646},{},[647],{"type":34,"value":648},"plus",{"type":34,"value":650}," eine Lipase über dem Dreifachen des oberen Grenzwerts ",{"type":21,"tag":30,"props":652,"children":653},{},[654],{"type":34,"value":648},{"type":34,"value":656}," Bildgebung (",{"type":21,"tag":91,"props":658,"children":661},{"href":659,"rel":660},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[169],[662],{"type":34,"value":663},"Banks et al., Gut 2013",{"type":34,"value":665},"). Ein einzelner Laborwert erfüllt das nicht, und der Sprung von „deine Lipase ist erhöht\" zu „deine Bauchspeicheldrüse überlastet sich ins Versagen\" ist durch nichts gedeckt.",{"type":21,"tag":125,"props":667,"children":669},{"id":668},"behauptung-3-die-fettleber-kaskade",[670],{"type":34,"value":671},"Behauptung 3: die „Fettleber-Kaskade\"",{"type":21,"tag":26,"props":673,"children":674},{},[675],{"type":34,"value":676},"Das ist die zentrale Umkehrung — und die, bei der es sich am meisten lohnt, recht zu haben.",{"type":21,"tag":26,"props":678,"children":679},{},[680],{"type":21,"tag":344,"props":681,"children":684},{"alt":682,"src":683},"Retatrutid senkt das Leberfett in klinischen Studien deutlich","\u002Fassets\u002Freta_liverfat.png",[],{"type":21,"tag":26,"props":686,"children":687},{},[688,690,695,697,702,704,709,711,716,718,723,725,730],{"type":34,"value":689},"Er stellt Retatrutid so dar, als würde es die Leber überlasten und schädigen — eine „Fettleber-Kaskade\", eine „Leberüberlastung\". Die Studiendaten zeigen ",{"type":21,"tag":42,"props":691,"children":692},{},[693],{"type":34,"value":694},"das glatte Gegenteil.",{"type":34,"value":696}," In der Phase-2-Leberfett-Studie senkte Retatrutid das Leberfett dosisabhängig: nach 48 Wochen ",{"type":21,"tag":42,"props":698,"children":699},{},[700],{"type":34,"value":701},"−81,7 %",{"type":34,"value":703}," bei 8 mg und ",{"type":21,"tag":42,"props":705,"children":706},{},[707],{"type":34,"value":708},"−86,0 %",{"type":34,"value":710}," bei 12 mg, gegenüber −4,6 % unter Placebo. In der Höchstdosis-Gruppe ",{"type":21,"tag":42,"props":712,"children":713},{},[714],{"type":34,"value":715},"fiel bei rund 93 % der Patienten das Leberfett unter die 5-%-Schwelle",{"type":34,"value":717}," — medizinisch gesehen eine Normalisierung ihrer Fettleber (",{"type":21,"tag":91,"props":719,"children":721},{"href":285,"rel":720},[169],[722],{"type":34,"value":289},{"type":34,"value":724},"). Das gehört zu den größten Leberfett-Reduktionen, die in der bisherigen klinischen Entwicklung des Wirkstoffs berichtet wurden. Retatrutid ist keine versteckte Lebergefahr; es wird ",{"type":21,"tag":42,"props":726,"children":727},{},[728],{"type":34,"value":729},"als Therapie gegen die Fettleber (MASLD)",{"type":34,"value":731}," entwickelt. Sein Nettoeffekt auf die Leber ist in kontrollierten Studien zutiefst schützend — das Gegenteil der Kaskade, die er beschreibt.",{"type":21,"tag":125,"props":733,"children":735},{"id":734},"was-er-richtig-sieht",[736],{"type":34,"value":737},"Was er richtig sieht",{"type":21,"tag":26,"props":739,"children":740},{},[741],{"type":34,"value":742},"Ein fairer Faktencheck benennt die Treffer, nicht nur die Fehlschüsse — und zwei seiner Grundgedanken sind berechtigt.",{"type":21,"tag":26,"props":744,"children":745},{},[746,748,753,755,760,762,767,768,775,777,784],{"type":34,"value":747},"Er hat recht, dass man ",{"type":21,"tag":42,"props":749,"children":750},{},[751],{"type":34,"value":752},"das Medikament nicht wegen eines einzelnen, beschwerdefreien Lipase-Anstiegs panisch absetzen",{"type":34,"value":754}," sollte; das deckt sich tatsächlich mit dem, was gastroenterologische Leitlinien nahelegen. Und er hat recht, dass schneller Gewichtsverlust unter diesen Medikamenten ",{"type":21,"tag":42,"props":756,"children":757},{},[758],{"type":34,"value":759},"Magermasse",{"type":34,"value":761}," kostet — etwa ein Viertel bis fast die Hälfte des verlorenen Gewichts kann fettfreie Masse sein, ein Großteil davon Muskulatur (",{"type":21,"tag":91,"props":763,"children":765},{"href":311,"rel":764},[169],[766],{"type":34,"value":315},{"type":34,"value":216},{"type":21,"tag":91,"props":769,"children":772},{"href":770,"rel":771},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[169],[773],{"type":34,"value":774},"Tinsley et al., 2024",{"type":34,"value":776},"), weshalb Eiweißzufuhr und Krafttraining in jeden ernstzunehmenden Plan gehören (",{"type":21,"tag":91,"props":778,"children":781},{"href":779,"rel":780},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[169],[782],{"type":34,"value":783},"Locatelli et al., Diabetes Care 2024",{"type":34,"value":785},"). Diese Punkte sind echt. Das Problem ist die Verpackung drumherum.",{"type":21,"tag":125,"props":787,"children":789},{"id":788},"das-muster",[790],{"type":34,"value":791},"Das Muster",{"type":21,"tag":26,"props":793,"children":794},{},[795],{"type":34,"value":796},"So wie wir es sehen, ist die Struktur hier eine altbekannte: Echte Fachbegriffe werden benutzt, um Autorität vorzuspiegeln; eine furchteinflößende „Schadenskaskade\" wird konstruiert, die unserer Lesart der Studiendaten nach von der Evidenz nicht getragen wird; andere Stimmen werden als „Fehlinformation\" abgestempelt; und das vorgeschlagene Heilmittel ist ein kostenpflichtiges Protokoll plus Peptide aus dem eigenen Shop des Autors. Wir behaupten nicht, seine Absicht zu kennen — wir beschreiben die Wirkung, wie wir sie sehen, und den kommerziellen Kontext kannst du selbst gewichten.",{"type":21,"tag":26,"props":798,"children":799},{},[800],{"type":34,"value":801},"Retatrutid ist eine ernstzunehmende Prüfsubstanz mit einem realen Nebenwirkungsprofil (überwiegend im Magen-Darm-Trakt, dosisabhängig, am stärksten während der Dosissteigerung) und echten offenen Fragen zu Langzeitanwendung und Muskelverlust. Es verdient Vorsicht und einen verordnenden Arzt. Was es nicht verdient, ist ein erfundenes Organversagen-Narrativ von jemandem, der das Gegenmittel verkauft.",{"type":21,"tag":803,"props":804,"children":805},"hr",{},[],{"type":21,"tag":125,"props":807,"children":809},{"id":808},"das-vollständige-wissenschaftliche-bild",[810],{"type":34,"value":811},"Das vollständige wissenschaftliche Bild",{"type":21,"tag":26,"props":813,"children":814},{},[815],{"type":34,"value":816},"Der Abschnitt oben ist das Urteil. Dieser Teil ist die Hausaufgabe: eine mit Quellen unterlegte Einführung in das, was diese Medikamente tatsächlich tun — damit du die Behauptungen selbst beurteilen kannst, statt irgendjemandem aufs Wort zu glauben, uns oder ihm. Er ist bewusst dicht.",{"type":21,"tag":125,"props":818,"children":820},{"id":819},"von-nafld-zu-masld",[821],{"type":34,"value":822},"Von NAFLD zu MASLD",{"type":21,"tag":26,"props":824,"children":825},{},[826,828,833,835,842],{"type":34,"value":827},"Jahrzehntelang hieß die Fettansammlung in der Leber ohne nennenswerten Alkoholkonsum nicht-alkoholische Fettlebererkrankung (NAFLD) — heute die häufigste chronische Lebererkrankung der Welt, die rund 30–38 % der Erwachsenen betrifft. 2023 taufte ein internationaler Konsens sie in ",{"type":21,"tag":42,"props":829,"children":830},{},[831],{"type":34,"value":832},"MASLD — metabolic dysfunction-associated steatotic liver disease",{"type":34,"value":834}," — um, um die metabolische Grundursache in den Vordergrund zu rücken, statt die Krankheit über das zu definieren, was sie nicht ist (",{"type":21,"tag":91,"props":836,"children":839},{"href":837,"rel":838},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[169],[840],{"type":34,"value":841},"Rinella et al., 2023",{"type":34,"value":233},{"type":21,"tag":26,"props":844,"children":845},{},[846,848,853,855,862,864,869],{"type":34,"value":847},"Den Verlauf beschreibt ein ",{"type":21,"tag":42,"props":849,"children":850},{},[851],{"type":34,"value":852},"„Multiple-Hit\"-Modell",{"type":34,"value":854},": Der erste Schlag ist das Fett, das sich in den Leberzellen einlagert und die Leber dann anfällig für weitere Schäden macht — oxidativer Stress, mitochondriale Dysfunktion, Darm-Leber-Dysbiose, Entzündung (",{"type":21,"tag":91,"props":856,"children":859},{"href":857,"rel":858},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[169],[860],{"type":34,"value":861},"Buzzetti et al., 2016",{"type":34,"value":863},"). Das Spektrum reicht von der einfachen Steatose über die Steatohepatitis (MASH) mit Entzündung und Zellschädigung bis hin zu Fibrose, Zirrhose und Leberkrebs. Treiber dieser Progression ist die ",{"type":21,"tag":42,"props":865,"children":866},{},[867],{"type":34,"value":868},"Lipotoxizität",{"type":34,"value":870}," — nicht das träge Triglycerid selbst, sondern giftige Lipid-Zwischenprodukte wie Ceramide und Diacylglycerole, die die Zellmaschinerie schädigen und entzündliche Signalwege anschalten.",{"type":21,"tag":125,"props":872,"children":874},{"id":873},"selektive-hepatische-insulinresistenz",[875],{"type":34,"value":876},"Selektive hepatische Insulinresistenz",{"type":21,"tag":26,"props":878,"children":879},{},[880,882,889,890,897],{"type":34,"value":881},"Eine der wichtigsten Ideen hier, maßgeblich von Samuel und Shulman entwickelt, löst ein Paradoxon auf: warum eine diabetische Leber das Insulinsignal, die Glukoseproduktion zu stoppen, ignoriert, dem Insulinsignal, Fett herzustellen, aber weiter brav gehorcht (",{"type":21,"tag":91,"props":883,"children":886},{"href":884,"rel":885},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[169],[887],{"type":34,"value":888},"Samuel & Shulman, JCI 2016",{"type":34,"value":216},{"type":21,"tag":91,"props":891,"children":894},{"href":892,"rel":893},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[169],[895],{"type":34,"value":896},"Cell Metabolism 2018",{"type":34,"value":233},{"type":21,"tag":26,"props":899,"children":900},{},[901,903,908,910,915,917,924,926,931],{"type":34,"value":902},"Der Mechanismus: Während sich Fett in der Leber ansammelt, staut sich ",{"type":21,"tag":42,"props":904,"children":905},{},[906],{"type":34,"value":907},"Diacylglycerol",{"type":34,"value":909}," an und aktiviert ein Enzym (PKCε), das das frühe Insulinsignal blockiert. Insulin kann die Glukoseausschüttung nicht mehr unterdrücken — der Blutzucker steigt —, aber die fettproduzierende Maschinerie läuft mit reichlich Substrat und hohen Insulinspiegeln munter weiter. Nimm noch dazu, dass insulinresistentes Fettgewebe freie Fettsäuren direkt in die Leber schickt, und du hast eine sich selbst verstärkende Schleife der Fetteinlagerung. Isotopenstudien beziffern den Zufluss: Bei Fettleberpatienten stammen etwa ",{"type":21,"tag":42,"props":911,"children":912},{},[913],{"type":34,"value":914},"59 % des gespeicherten Leber-Triglycerids aus zirkulierenden freien Fettsäuren",{"type":34,"value":916}," (periphere Lipolyse), ~26 % aus der De-novo-Lipogenese und ~15 % aus der Nahrung (",{"type":21,"tag":91,"props":918,"children":921},{"href":919,"rel":920},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[169],[922],{"type":34,"value":923},"Donnelly et al., JCI 2005",{"type":34,"value":925},"). Das ist die echte Biologie, auf die das Video anspielt — und genau deshalb hilft ein Medikament, das diesen Fettzufluss ",{"type":21,"tag":30,"props":927,"children":928},{},[929],{"type":34,"value":930},"drosselt",{"type":34,"value":932},", statt zu schaden.",{"type":21,"tag":125,"props":934,"children":936},{"id":935},"was-glukagon-wirklich-tut-und-der-weißfett-mythos",[937],{"type":34,"value":938},"Was Glukagon wirklich tut — und der Weißfett-Mythos",{"type":21,"tag":26,"props":940,"children":941},{},[942,944,949,950,955,956,963,964,970],{"type":34,"value":943},"Glukagon, lange bloß als Gegenspieler des Insulins abgestempelt, gilt heute als breiter Regulator des Energie- und Fettstoffwechsels. Sein Hauptziel ist die Leber, wo es die Glukosefreisetzung anstößt und — wichtig — über einen cAMP\u002FPKA-Signalweg und einen Calcium-Freisetzungsmechanismus, der den Fettabbau in der Leber aktiviert, ",{"type":21,"tag":42,"props":945,"children":946},{},[947],{"type":34,"value":948},"die Fettoxidation antreibt und die Neubildung von Fett bremst",{"type":34,"value":250},{"type":21,"tag":91,"props":951,"children":953},{"href":210,"rel":952},[169],[954],{"type":34,"value":214},{"type":34,"value":216},{"type":21,"tag":91,"props":957,"children":960},{"href":958,"rel":959},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[169],[961],{"type":34,"value":962},"Galsgaard et al., 2019",{"type":34,"value":216},{"type":21,"tag":91,"props":965,"children":967},{"href":555,"rel":966},[169],[968],{"type":34,"value":969},"Kajani et al., 2024",{"type":34,"value":971},"). Genau diese „Fettverbrennung\" in der Leber ist der Grund, warum die Arzneimittelentwickler Retatrutid ein Glukagon-Signal mitgegeben haben.",{"type":21,"tag":26,"props":973,"children":974},{},[975,977,982,984,989,991,996,997,1003,1005,1010],{"type":34,"value":976},"Aber — und das ist die Mythos-Korrektur — diese Wirkung ist ",{"type":21,"tag":42,"props":978,"children":979},{},[980],{"type":34,"value":981},"hepatisch, nicht peripher.",{"type":34,"value":983}," Alte Reagenzglas-Experimente zeigten, dass isolierte Fettzellen Fett abbauen, wenn man sie in Glukagon badet, aber nur bei Konzentrationen, die 10- bis 100-mal höher liegen, als der Körper sie je produziert. Neuere Arbeiten stellen es klar: Schaltet man den Glukagonrezeptor im Fettgewebe aus, bleibt der Fettstoffwechsel unverändert (",{"type":21,"tag":91,"props":985,"children":987},{"href":219,"rel":986},[169],[988],{"type":34,"value":223},{"type":34,"value":990},"); gibt man Menschen physiologisches Glukagon, rührt sich die Lipolyse im Bauchfett nicht (",{"type":21,"tag":91,"props":992,"children":994},{"href":227,"rel":993},[169],[995],{"type":34,"value":231},{"type":34,"value":216},{"type":21,"tag":91,"props":998,"children":1000},{"href":529,"rel":999},[169],[1001],{"type":34,"value":1002},"Jensen et al., 1991",{"type":34,"value":1004},"). Der Gewichtsverlust unter glukagonhaltigen Medikamenten kommt von gedämpftem Appetit, erhöhtem Energieumsatz und der Fettoxidation in der ",{"type":21,"tag":42,"props":1006,"children":1007},{},[1008],{"type":34,"value":1009},"Leber",{"type":34,"value":1011}," — nicht davon, dass Glukagon dein Bauchfett auflöst und deine Organe damit überschwemmt.",{"type":21,"tag":125,"props":1013,"children":1015},{"id":1014},"der-poly-agonisten-sprung-von-semaglutid-zu-retatrutid",[1016],{"type":34,"value":1017},"Der Poly-Agonisten-Sprung: von Semaglutid zu Retatrutid",{"type":21,"tag":26,"props":1019,"children":1020},{},[1021,1023,1028,1030,1037,1039,1044,1045,1052,1054,1061,1062,1069],{"type":34,"value":1022},"Inkretin-Medikamente sind Nachbauten von Darmhormonen, so konstruiert, dass sie dem schnellen Abbau widerstehen und länger wirken. Die erste Welle waren GLP-1-Mono-Agonisten: Semaglutid erreichte in seiner zulassungsrelevanten Adipositas-Studie im Schnitt etwa ",{"type":21,"tag":42,"props":1024,"children":1025},{},[1026],{"type":34,"value":1027},"14,9 %",{"type":34,"value":1029}," Gewichtsverlust (",{"type":21,"tag":91,"props":1031,"children":1034},{"href":1032,"rel":1033},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[169],[1035],{"type":34,"value":1036},"STEP 1, Wilding et al., NEJM 2021",{"type":34,"value":1038},"). Als Nächstes kam der duale GLP-1\u002FGIP-Agonismus: Tirzepatid schaffte bis zu ",{"type":21,"tag":42,"props":1040,"children":1041},{},[1042],{"type":34,"value":1043},"20,9 %",{"type":34,"value":250},{"type":21,"tag":91,"props":1046,"children":1049},{"href":1047,"rel":1048},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[169],[1050],{"type":34,"value":1051},"SURMOUNT-1, Jastreboff et al., NEJM 2022",{"type":34,"value":1053},"). Zur Physiologie, wie diese Hormone zusammenspielen, siehe ",{"type":21,"tag":91,"props":1055,"children":1058},{"href":1056,"rel":1057},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[169],[1059],{"type":34,"value":1060},"Holst, Nature Metabolism 2024",{"type":34,"value":457},{"type":21,"tag":91,"props":1063,"children":1066},{"href":1064,"rel":1065},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[169],[1067],{"type":34,"value":1068},"Nauck et al., 2021",{"type":34,"value":183},{"type":21,"tag":26,"props":1071,"children":1072},{},[1073,1075,1080,1082,1089],{"type":34,"value":1074},"Retatrutid (LY3437943) geht noch einen Schritt weiter: ein einziges Molekül, das ",{"type":21,"tag":42,"props":1076,"children":1077},{},[1078],{"type":34,"value":1079},"GLP-1-, GIP- und Glukagon",{"type":34,"value":1081},"-Rezeptoren zugleich anspricht (",{"type":21,"tag":91,"props":1083,"children":1086},{"href":1084,"rel":1085},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[169],[1087],{"type":34,"value":1088},"Studie NCT04881760",{"type":34,"value":1090},"). Der Glukagon-Arm bringt Fettoxidation in der Leber und Energieumsatz mit; die GLP-1- und GIP-Arme liefern Appetitzügelung, Insulinunterstützung und — entscheidend — heben Glukagons Neigung auf, den Blutzucker in die Höhe zu treiben.",{"type":21,"tag":26,"props":1092,"children":1093},{},[1094,1096,1101,1103,1110,1112,1118,1120,1125],{"type":34,"value":1095},"Eine Anmerkung zur Benennung: Die ",{"type":21,"tag":42,"props":1097,"children":1098},{},[1099],{"type":34,"value":1100},"Phase-2",{"type":34,"value":1102},"-Daten unten stammen aus ",{"type":21,"tag":91,"props":1104,"children":1107},{"href":1105,"rel":1106},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[169],[1108],{"type":34,"value":1109},"Jastreboff et al., NEJM 2023",{"type":34,"value":1111}," und der ",{"type":21,"tag":91,"props":1113,"children":1115},{"href":285,"rel":1114},[169],[1116],{"type":34,"value":1117},"MASLD-Substudie, Sanyal et al., Nature Medicine 2024",{"type":34,"value":1119},". „TRIUMPH\" ist das spätere ",{"type":21,"tag":30,"props":1121,"children":1122},{},[1123],{"type":34,"value":1124},"Phase-3",{"type":34,"value":1126},"-Programm — lass dir also von niemandem Phase-2-Zahlen als TRIUMPH-1-Ergebnisse andrehen.",{"type":21,"tag":26,"props":1128,"children":1129},{},[1130,1135,1137,1143],{"type":21,"tag":42,"props":1131,"children":1132},{},[1133],{"type":34,"value":1134},"Gewichtsveränderung nach 48 Wochen",{"type":34,"value":1136}," (Phase 2, n=338; ",{"type":21,"tag":91,"props":1138,"children":1140},{"href":1105,"rel":1139},[169],[1141],{"type":34,"value":1142},"Jastreboff et al., 2023",{"type":34,"value":1144},"):",{"type":21,"tag":1146,"props":1147,"children":1148},"table",{},[1149,1168],{"type":21,"tag":1150,"props":1151,"children":1152},"thead",{},[1153],{"type":21,"tag":1154,"props":1155,"children":1156},"tr",{},[1157,1163],{"type":21,"tag":1158,"props":1159,"children":1160},"th",{},[1161],{"type":34,"value":1162},"Wöchentliche Dosis",{"type":21,"tag":1158,"props":1164,"children":1165},{},[1166],{"type":34,"value":1167},"Mittlere Gewichtsveränderung",{"type":21,"tag":1169,"props":1170,"children":1171},"tbody",{},[1172,1186,1199,1212,1225],{"type":21,"tag":1154,"props":1173,"children":1174},{},[1175,1181],{"type":21,"tag":1176,"props":1177,"children":1178},"td",{},[1179],{"type":34,"value":1180},"Placebo",{"type":21,"tag":1176,"props":1182,"children":1183},{},[1184],{"type":34,"value":1185},"−2,1 %",{"type":21,"tag":1154,"props":1187,"children":1188},{},[1189,1194],{"type":21,"tag":1176,"props":1190,"children":1191},{},[1192],{"type":34,"value":1193},"Retatrutid 1 mg",{"type":21,"tag":1176,"props":1195,"children":1196},{},[1197],{"type":34,"value":1198},"−8,7 %",{"type":21,"tag":1154,"props":1200,"children":1201},{},[1202,1207],{"type":21,"tag":1176,"props":1203,"children":1204},{},[1205],{"type":34,"value":1206},"Retatrutid 4 mg",{"type":21,"tag":1176,"props":1208,"children":1209},{},[1210],{"type":34,"value":1211},"−17,1 %",{"type":21,"tag":1154,"props":1213,"children":1214},{},[1215,1220],{"type":21,"tag":1176,"props":1216,"children":1217},{},[1218],{"type":34,"value":1219},"Retatrutid 8 mg",{"type":21,"tag":1176,"props":1221,"children":1222},{},[1223],{"type":34,"value":1224},"−22,8 %",{"type":21,"tag":1154,"props":1226,"children":1227},{},[1228,1233],{"type":21,"tag":1176,"props":1229,"children":1230},{},[1231],{"type":34,"value":1232},"Retatrutid 12 mg",{"type":21,"tag":1176,"props":1234,"children":1235},{},[1236],{"type":34,"value":1237},"−24,2 %",{"type":21,"tag":26,"props":1239,"children":1240},{},[1241,1246,1248,1254],{"type":21,"tag":42,"props":1242,"children":1243},{},[1244],{"type":34,"value":1245},"Leberfett-Veränderung nach 48 Wochen",{"type":34,"value":1247}," (MASLD-Substudie, n=98; ",{"type":21,"tag":91,"props":1249,"children":1251},{"href":285,"rel":1250},[169],[1252],{"type":34,"value":1253},"Sanyal et al., 2024",{"type":34,"value":1144},{"type":21,"tag":1146,"props":1256,"children":1257},{},[1258,1278],{"type":21,"tag":1150,"props":1259,"children":1260},{},[1261],{"type":21,"tag":1154,"props":1262,"children":1263},{},[1264,1268,1273],{"type":21,"tag":1158,"props":1265,"children":1266},{},[1267],{"type":34,"value":1162},{"type":21,"tag":1158,"props":1269,"children":1270},{},[1271],{"type":34,"value":1272},"Relative Leberfett-Veränderung",{"type":21,"tag":1158,"props":1274,"children":1275},{},[1276],{"type":34,"value":1277},"Leberfett normalisiert (\u003C5 %)",{"type":21,"tag":1169,"props":1279,"children":1280},{},[1281,1298,1315,1331],{"type":21,"tag":1154,"props":1282,"children":1283},{},[1284,1288,1293],{"type":21,"tag":1176,"props":1285,"children":1286},{},[1287],{"type":34,"value":1180},{"type":21,"tag":1176,"props":1289,"children":1290},{},[1291],{"type":34,"value":1292},"−4,6 %",{"type":21,"tag":1176,"props":1294,"children":1295},{},[1296],{"type":34,"value":1297},"0 %",{"type":21,"tag":1154,"props":1299,"children":1300},{},[1301,1305,1310],{"type":21,"tag":1176,"props":1302,"children":1303},{},[1304],{"type":34,"value":1193},{"type":21,"tag":1176,"props":1306,"children":1307},{},[1308],{"type":34,"value":1309},"−51,3 %",{"type":21,"tag":1176,"props":1311,"children":1312},{},[1313],{"type":34,"value":1314},">50 %",{"type":21,"tag":1154,"props":1316,"children":1317},{},[1318,1322,1326],{"type":21,"tag":1176,"props":1319,"children":1320},{},[1321],{"type":34,"value":1219},{"type":21,"tag":1176,"props":1323,"children":1324},{},[1325],{"type":34,"value":701},{"type":21,"tag":1176,"props":1327,"children":1328},{},[1329],{"type":34,"value":1330},"—",{"type":21,"tag":1154,"props":1332,"children":1333},{},[1334,1338,1342],{"type":21,"tag":1176,"props":1335,"children":1336},{},[1337],{"type":34,"value":1232},{"type":21,"tag":1176,"props":1339,"children":1340},{},[1341],{"type":34,"value":708},{"type":21,"tag":1176,"props":1343,"children":1344},{},[1345],{"type":34,"value":1346},"~93 %",{"type":21,"tag":26,"props":1348,"children":1349},{},[1350],{"type":34,"value":1351},"Knapp ein Viertel des Körpergewichts weg in weniger als einem Jahr, in einer Größenordnung, die zuvor nur die bariatrische Chirurgie erreichte — und eine Fettleber, die bei mehr als neun von zehn Patienten unter der Höchstdosis normalisiert war. Das sind die Daten, die ein „Leberüberlastungs\"-Narrativ ausblenden muss.",{"type":21,"tag":125,"props":1353,"children":1355},{"id":1354},"gastrointestinale-effekte-und-die-anästhesie-frage",[1356],{"type":34,"value":1357},"Gastrointestinale Effekte und die Anästhesie-Frage",{"type":21,"tag":26,"props":1359,"children":1360},{},[1361,1363,1368,1370,1375],{"type":34,"value":1362},"Der Preis dieser Wirksamkeit liegt vor allem im Magen-Darm-Trakt. Verlangsamte Magenentleerung und Übelkeitssignale im Hirnstamm machen ",{"type":21,"tag":42,"props":1364,"children":1365},{},[1366],{"type":34,"value":1367},"Übelkeit, Erbrechen, Durchfall und Verstopfung",{"type":34,"value":1369}," zu den häufigen Nebenwirkungen — dosisabhängig, am stärksten während der Dosissteigerung und meist vorübergehend (",{"type":21,"tag":91,"props":1371,"children":1373},{"href":1105,"rel":1372},[169],[1374],{"type":34,"value":1142},{"type":34,"value":1376},"). Eine langsame Titration (niedrig einsteigen und behutsam hochtasten) ist die Standard-Gegenmaßnahme.",{"type":21,"tag":26,"props":1378,"children":1379},{},[1380,1382,1389,1390,1397,1399,1406,1408,1415,1417,1421],{"type":34,"value":1381},"Eine reale Folge hat eine echte medizinische Debatte ausgelöst: Weil diese Medikamente die Magenentleerung verlangsamen, kann Nahrung länger im Magen bleiben — das erhöht die Wahrscheinlichkeit von Restmageninhalt vor einer Narkose und damit ein theoretisches Aspirationsrisiko. Metaanalysen finden tatsächlich einen deutlich höheren Restmageninhalt bei Anwendern (",{"type":21,"tag":91,"props":1383,"children":1386},{"href":1384,"rel":1385},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[169],[1387],{"type":34,"value":1388},"do Nascimento et al., 2024",{"type":34,"value":216},{"type":21,"tag":91,"props":1391,"children":1394},{"href":1392,"rel":1393},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[169],[1395],{"type":34,"value":1396},"Tan et al., 2025",{"type":34,"value":1398},"), auch wenn echte Aspirationsereignisse selten bleiben (",{"type":21,"tag":91,"props":1400,"children":1403},{"href":1401,"rel":1402},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[169],[1404],{"type":34,"value":1405},"Jalleh et al., JCEM 2024",{"type":34,"value":1407},"). Anästhesie-Fachgesellschaften raten inzwischen, das Medikament vor planbaren Eingriffen zu pausieren (",{"type":21,"tag":91,"props":1409,"children":1412},{"href":1410,"rel":1411},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[169],[1413],{"type":34,"value":1414},"ASA-Leitlinie, 2024",{"type":34,"value":1416},"). Das ist eine berechtigte, gut untersuchte Vorsichtsmaßnahme — und bemerkenswerterweise ",{"type":21,"tag":30,"props":1418,"children":1419},{},[1420],{"type":34,"value":198},{"type":34,"value":1422}," die, auf die sich das Video kapriziert.",{"type":21,"tag":125,"props":1424,"children":1426},{"id":1425},"die-bauchspeicheldrüse-wie-sie-funktioniert-und-die-lipase-frage",[1427],{"type":34,"value":1428},"Die Bauchspeicheldrüse: wie sie funktioniert, und die Lipase-Frage",{"type":21,"tag":26,"props":1430,"children":1431},{},[1432,1434,1440],{"type":34,"value":1433},"Über 90 % der Bauchspeicheldrüse sind exokrines Gewebe — Azinuszellen, die Verdauungsenzyme herstellen. Sie lagern inaktive Enzymvorstufen ein und geben sie auf Signal frei; eine vorzeitige Aktivierung noch in der Zelle ist das, was eine echte Pankreatitis ausmacht. Auf diesen Azinuszellen sitzen GLP-1-Rezeptoren, sodass die Medikamente die Enzymfreisetzung als ganz normalen, rezeptorvermittelten Effekt anstoßen (",{"type":21,"tag":91,"props":1435,"children":1437},{"href":595,"rel":1436},[169],[1438],{"type":34,"value":1439},"Hou… Williams et al., 2016",{"type":34,"value":233},{"type":21,"tag":26,"props":1442,"children":1443},{},[1444,1446,1451,1453,1459,1461,1466],{"type":34,"value":1445},"Deshalb sind milde Erhöhungen von Lipase und Amylase unter der Therapie so häufig — und deshalb sind sie meist bedeutungslos. Es ist stimuliertes Enzym-",{"type":21,"tag":30,"props":1447,"children":1448},{},[1449],{"type":34,"value":1450},"Leck",{"type":34,"value":1452},", keine Gewebezerstörung. Die Studienlage (siehe oben) zeigt, dass diese Anstiege keine Pankreatitis vorhersagen (",{"type":21,"tag":91,"props":1454,"children":1456},{"href":253,"rel":1455},[169],[1457],{"type":34,"value":1458},"Steinberg et al., 2017",{"type":34,"value":1460},"), und gepoolte Daten zeigen kein erhöhtes Pankreatitis-Risiko gegenüber Placebo. Das tatsächlich vorhandene Grundrisiko folgt der Population — Menschen mit Adipositas und Typ-2-Diabetes bringen ohnehin ein höheres Ausgangsrisiko für eine Pankreatitis mit, durch Gallensteine und hohe Triglyceride, ganz unabhängig von jedem Medikament. Dass genau diese Auslöser mitbehandelt werden, ist vermutlich der Grund, warum einige Daten sogar eine ",{"type":21,"tag":42,"props":1462,"children":1463},{},[1464],{"type":34,"value":1465},"niedrigere",{"type":34,"value":1467}," Rückfallrate unter GLP-1-Therapie zeigen.",{"type":21,"tag":125,"props":1469,"children":1471},{"id":1470},"der-eigentliche-vorbehalt-verlust-von-magermasse",[1472],{"type":34,"value":1473},"Der eigentliche Vorbehalt: Verlust von Magermasse",{"type":21,"tag":26,"props":1475,"children":1476},{},[1477,1479,1484,1486,1491,1492,1497,1499,1505],{"type":34,"value":1478},"Wenn es eine Warnung gibt, die die Sendezeit verdient, die das Video für Phantom-Organschäden verpulvert, dann diese. Über die Inkretin-Studien hinweg ist ein erheblicher Teil des verlorenen Gewichts ",{"type":21,"tag":42,"props":1480,"children":1481},{},[1482],{"type":34,"value":1483},"fettfreie Masse",{"type":34,"value":1485}," — etwa 25–40 %, ein Großteil davon Skelettmuskulatur (",{"type":21,"tag":91,"props":1487,"children":1489},{"href":311,"rel":1488},[169],[1490],{"type":34,"value":315},{"type":34,"value":216},{"type":21,"tag":91,"props":1493,"children":1495},{"href":770,"rel":1494},[169],[1496],{"type":34,"value":774},{"type":34,"value":1498},"). Das ist nichts, was nur diese Medikamente betrifft — jeder große, schnelle Gewichtsverlust tut das —, aber Muskelverlust senkt den Grundumsatz (und befeuert den Rebound nach dem Absetzen), verringert die Insulinsensitivität und erhöht bei älteren Menschen Gebrechlichkeit und Sturzrisiko. Die evidenzbasierte Lösung ist unglamourös: genug Eiweiß und progressives Krafttraining begleitend zum Medikament (",{"type":21,"tag":91,"props":1500,"children":1502},{"href":779,"rel":1501},[169],[1503],{"type":34,"value":1504},"Locatelli et al., 2024",{"type":34,"value":233},{"type":21,"tag":125,"props":1507,"children":1509},{"id":1508},"neue-grenzen-immunmetabolismus-und-krebs",[1510],{"type":34,"value":1511},"Neue Grenzen: Immunmetabolismus und Krebs",{"type":21,"tag":26,"props":1513,"children":1514},{},[1515,1517,1524],{"type":34,"value":1516},"Zum Schluss ein Blick darauf, wohin die Forschung steuert. Adipositas heizt chronische Entzündungen an und „erschöpft\" metabolisch die Immunzellen, die Tumoren bekämpfen. Frühe Arbeiten legen nahe, dass GLP-1-Medikamente das teilweise umkehren können: In adipösen Mausmodellen für Lungenkrebs bremste ein GLP-1-Agonist das Tumorwachstum und verbesserte das antitumorale Immunmilieu — ein Effekt, der sich nur bei adipösen Tieren zeigte (",{"type":21,"tag":91,"props":1518,"children":1521},{"href":1519,"rel":1520},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[169],[1522],{"type":34,"value":1523},"Pachimatla… Sanghvi et al., JCI Insight 2025",{"type":34,"value":1525},"). Das ist präklinisch und ganz am Anfang, aber es deutet an, dass die Korrektur metabolischer Störungen einen Nutzen weit über die Waage hinaus haben könnte.",{"type":21,"tag":125,"props":1527,"children":1529},{"id":1528},"das-ehrliche-urteil",[1530],{"type":34,"value":1531},"Das ehrliche Urteil",{"type":21,"tag":26,"props":1533,"children":1534},{},[1535,1537,1542,1544,1549,1551,1555,1556,1561,1563,1567],{"type":34,"value":1536},"Fügt man die Evidenz zusammen, ergibt sich das Gegenteil dessen, was das Video zeichnet. In kontrollierten Studien ",{"type":21,"tag":42,"props":1538,"children":1539},{},[1540],{"type":34,"value":1541},"senkt",{"type":34,"value":1543}," Retatrutid das Leberfett drastisch, ",{"type":21,"tag":42,"props":1545,"children":1546},{},[1547],{"type":34,"value":1548},"erhöht",{"type":34,"value":1550}," das Pankreatitis-Risiko ",{"type":21,"tag":42,"props":1552,"children":1553},{},[1554],{"type":34,"value":198},{"type":34,"value":457},{"type":21,"tag":42,"props":1557,"children":1558},{},[1559],{"type":34,"value":1560},"löst",{"type":34,"value":1562}," dein Körperfett ",{"type":21,"tag":42,"props":1564,"children":1565},{},[1566],{"type":34,"value":198},{"type":34,"value":1568}," durch irgendeine Glukagon-Flut auf. Die echten Vorbehalte — Muskelverlust, Magen-Darm-Effekte, die Anästhesie-Wechselwirkung und die nüchterne Tatsache, dass Graumarkt-Ware unreguliert ist und womöglich nicht das enthält, was auf dem Etikett steht — sind genau die, bei denen ein Verkäufer, der dir Peptide verkaufen will, am wenigsten Anreiz hat, zu verweilen.",{"type":21,"tag":26,"props":1570,"children":1571},{},[1572,1574,1578,1580,1586,1588,1594],{"type":34,"value":1573},"Wenn du irgendetwas davon in Erwägung ziehst oder es bereits anwendest, ist der richtige Schritt nicht ein 45-Minuten-Video und ein Kaufbutton. Es sind Blutwerte, ein echter Verordner und ehrliche Erwartungen. Wenn sich etwas nicht richtig anfühlt, dann ",{"type":21,"tag":42,"props":1575,"children":1576},{},[1577],{"type":34,"value":113},{"type":34,"value":1579},", bevor du einem Protokoll vertraust, das die Person verkauft, die dich auf YouTube diagnostiziert hat. Für die Studiendosen, wie sie in der veröffentlichten Literatur berichtet werden, siehe unsere ",{"type":21,"tag":91,"props":1581,"children":1583},{"href":1582},"\u002Fglp1\u002Fretatrutide",[1584],{"type":34,"value":1585},"Retatrutid-Referenz",{"type":34,"value":1587},"; um zuerst die Wirkstoffklasse zu verstehen, fang mit ",{"type":21,"tag":91,"props":1589,"children":1591},{"href":1590},"\u002Fwhat-are-peptides",[1592],{"type":34,"value":1593},"was Peptide sind",{"type":34,"value":1595}," an.",{"type":21,"tag":125,"props":1597,"children":1599},{"id":1598},"quellen",[1600],{"type":34,"value":1601},"Quellen",{"type":21,"tag":1603,"props":1604,"children":1605},"ol",{},[1606,1639,1671,1688,1710,1732,1756,1780,1803,1825,1848,1871,1895,1924,1947,1969,1991,2013,2035,2057,2079,2102,2124,2146,2168,2190,2211,2233,2255,2276,2298,2320,2338,2354,2371,2388],{"type":21,"tag":148,"props":1607,"children":1608},{},[1609,1611,1616,1617,1622,1624,1630,1632],{"type":34,"value":1610},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":21,"tag":42,"props":1612,"children":1613},{},[1614],{"type":34,"value":1615},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":34,"value":450},{"type":21,"tag":30,"props":1618,"children":1619},{},[1620],{"type":34,"value":1621},"N Engl J Med",{"type":34,"value":1623}," 2023. ",{"type":21,"tag":91,"props":1625,"children":1627},{"href":1105,"rel":1626},[169],[1628],{"type":34,"value":1629},"PubMed",{"type":34,"value":1631}," · ",{"type":21,"tag":91,"props":1633,"children":1636},{"href":1634,"rel":1635},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[169],[1637],{"type":34,"value":1638},"NEJM",{"type":21,"tag":148,"props":1640,"children":1641},{},[1642,1644,1649,1650,1655,1657,1663,1664],{"type":34,"value":1643},"Sanyal AJ, et al. ",{"type":21,"tag":42,"props":1645,"children":1646},{},[1647],{"type":34,"value":1648},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":34,"value":450},{"type":21,"tag":30,"props":1651,"children":1652},{},[1653],{"type":34,"value":1654},"Nature Medicine",{"type":34,"value":1656}," 2024. ",{"type":21,"tag":91,"props":1658,"children":1660},{"href":285,"rel":1659},[169],[1661],{"type":34,"value":1662},"PMC full text",{"type":34,"value":1631},{"type":21,"tag":91,"props":1665,"children":1668},{"href":1666,"rel":1667},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[169],[1669],{"type":34,"value":1670},"Nature",{"type":21,"tag":148,"props":1672,"children":1673},{},[1674,1676,1681,1682],{"type":34,"value":1675},"Phase-2 retatrutide obesity trial registration. ",{"type":21,"tag":30,"props":1677,"children":1678},{},[1679],{"type":34,"value":1680},"ClinicalTrials.gov",{"type":34,"value":450},{"type":21,"tag":91,"props":1683,"children":1685},{"href":1084,"rel":1684},[169],[1686],{"type":34,"value":1687},"NCT04881760",{"type":21,"tag":148,"props":1689,"children":1690},{},[1691,1693,1698,1699,1703,1705],{"type":34,"value":1692},"Perry RJ, et al. ",{"type":21,"tag":42,"props":1694,"children":1695},{},[1696],{"type":34,"value":1697},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":34,"value":450},{"type":21,"tag":30,"props":1700,"children":1701},{},[1702],{"type":34,"value":1670},{"type":34,"value":1704}," 2020. ",{"type":21,"tag":91,"props":1706,"children":1708},{"href":210,"rel":1707},[169],[1709],{"type":34,"value":1629},{"type":21,"tag":148,"props":1711,"children":1712},{},[1713,1715,1720,1721,1726,1727],{"type":34,"value":1714},"Kajani S, et al. ",{"type":21,"tag":42,"props":1716,"children":1717},{},[1718],{"type":34,"value":1719},"Hepatic glucagon action: beyond glucose mobilization.",{"type":34,"value":450},{"type":21,"tag":30,"props":1722,"children":1723},{},[1724],{"type":34,"value":1725},"Physiological Reviews",{"type":34,"value":1656},{"type":21,"tag":91,"props":1728,"children":1730},{"href":555,"rel":1729},[169],[1731],{"type":34,"value":1629},{"type":21,"tag":148,"props":1733,"children":1734},{},[1735,1737,1742,1743,1748,1750],{"type":34,"value":1736},"Galsgaard KD, et al. ",{"type":21,"tag":42,"props":1738,"children":1739},{},[1740],{"type":34,"value":1741},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":34,"value":450},{"type":21,"tag":30,"props":1744,"children":1745},{},[1746],{"type":34,"value":1747},"Front Physiol",{"type":34,"value":1749}," 2019. ",{"type":21,"tag":91,"props":1751,"children":1753},{"href":958,"rel":1752},[169],[1754],{"type":34,"value":1755},"Full text",{"type":21,"tag":148,"props":1757,"children":1758},{},[1759,1761,1766,1767,1772,1774],{"type":34,"value":1760},"Vasileva A, et al. ",{"type":21,"tag":42,"props":1762,"children":1763},{},[1764],{"type":34,"value":1765},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":34,"value":450},{"type":21,"tag":30,"props":1768,"children":1769},{},[1770],{"type":34,"value":1771},"Am J Physiol Endocrinol Metab",{"type":34,"value":1773}," 2022. ",{"type":21,"tag":91,"props":1775,"children":1777},{"href":219,"rel":1776},[169],[1778],{"type":34,"value":1779},"PMC",{"type":21,"tag":148,"props":1781,"children":1782},{},[1783,1785,1790,1791,1796,1798],{"type":34,"value":1784},"Gravholt CH, et al. ",{"type":21,"tag":42,"props":1786,"children":1787},{},[1788],{"type":34,"value":1789},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":34,"value":450},{"type":21,"tag":30,"props":1792,"children":1793},{},[1794],{"type":34,"value":1795},"JCEM",{"type":34,"value":1797}," 2001. ",{"type":21,"tag":91,"props":1799,"children":1801},{"href":227,"rel":1800},[169],[1802],{"type":34,"value":1629},{"type":21,"tag":148,"props":1804,"children":1805},{},[1806,1808,1813,1814,1818,1820],{"type":34,"value":1807},"Jensen MD, et al. ",{"type":21,"tag":42,"props":1809,"children":1810},{},[1811],{"type":34,"value":1812},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":34,"value":450},{"type":21,"tag":30,"props":1815,"children":1816},{},[1817],{"type":34,"value":1795},{"type":34,"value":1819}," 1991. ",{"type":21,"tag":91,"props":1821,"children":1823},{"href":529,"rel":1822},[169],[1824],{"type":34,"value":1629},{"type":21,"tag":148,"props":1826,"children":1827},{},[1828,1830,1835,1836,1841,1843],{"type":34,"value":1829},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":21,"tag":42,"props":1831,"children":1832},{},[1833],{"type":34,"value":1834},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":34,"value":450},{"type":21,"tag":30,"props":1837,"children":1838},{},[1839],{"type":34,"value":1840},"Am J Physiol Gastrointest Liver Physiol",{"type":34,"value":1842}," 2016. ",{"type":21,"tag":91,"props":1844,"children":1846},{"href":595,"rel":1845},[169],[1847],{"type":34,"value":1779},{"type":21,"tag":148,"props":1849,"children":1850},{},[1851,1853,1858,1859,1864,1866],{"type":34,"value":1852},"Steinberg WM, et al. ",{"type":21,"tag":42,"props":1854,"children":1855},{},[1856],{"type":34,"value":1857},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":34,"value":450},{"type":21,"tag":30,"props":1860,"children":1861},{},[1862],{"type":34,"value":1863},"Diabetes Care",{"type":34,"value":1865}," 2017. ",{"type":21,"tag":91,"props":1867,"children":1869},{"href":253,"rel":1868},[169],[1870],{"type":34,"value":1629},{"type":21,"tag":148,"props":1872,"children":1873},{},[1874,1876,1881,1883,1888,1890],{"type":34,"value":1875},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":21,"tag":30,"props":1877,"children":1878},{},[1879],{"type":34,"value":1880},"medRxiv",{"type":34,"value":1882}," 2026 (",{"type":21,"tag":42,"props":1884,"children":1885},{},[1886],{"type":34,"value":1887},"preprint, not yet peer-reviewed",{"type":34,"value":1889},"). ",{"type":21,"tag":91,"props":1891,"children":1893},{"href":621,"rel":1892},[169],[1894],{"type":34,"value":625},{"type":21,"tag":148,"props":1896,"children":1897},{},[1898,1900,1905,1906,1911,1912,1917,1918],{"type":34,"value":1899},"Nassar M, et al. ",{"type":21,"tag":42,"props":1901,"children":1902},{},[1903],{"type":34,"value":1904},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":34,"value":450},{"type":21,"tag":30,"props":1907,"children":1908},{},[1909],{"type":34,"value":1910},"ENDO 2024",{"type":34,"value":250},{"type":21,"tag":42,"props":1913,"children":1914},{},[1915],{"type":34,"value":1916},"conference abstract",{"type":34,"value":1889},{"type":21,"tag":91,"props":1919,"children":1921},{"href":637,"rel":1920},[169],[1922],{"type":34,"value":1923},"Press release",{"type":21,"tag":148,"props":1925,"children":1926},{},[1927,1929,1934,1935,1940,1942],{"type":34,"value":1928},"Banks PA, et al. ",{"type":21,"tag":42,"props":1930,"children":1931},{},[1932],{"type":34,"value":1933},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":34,"value":450},{"type":21,"tag":30,"props":1936,"children":1937},{},[1938],{"type":34,"value":1939},"Gut",{"type":34,"value":1941}," 2013. ",{"type":21,"tag":91,"props":1943,"children":1945},{"href":659,"rel":1944},[169],[1946],{"type":34,"value":1629},{"type":21,"tag":148,"props":1948,"children":1949},{},[1950,1952,1957,1958,1963,1964],{"type":34,"value":1951},"Rinella ME, et al. ",{"type":21,"tag":42,"props":1953,"children":1954},{},[1955],{"type":34,"value":1956},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":34,"value":450},{"type":21,"tag":30,"props":1959,"children":1960},{},[1961],{"type":34,"value":1962},"Hepatology \u002F J Hepatol",{"type":34,"value":1623},{"type":21,"tag":91,"props":1965,"children":1967},{"href":837,"rel":1966},[169],[1968],{"type":34,"value":1779},{"type":21,"tag":148,"props":1970,"children":1971},{},[1972,1974,1979,1980,1985,1986],{"type":34,"value":1973},"Samuel VT, Shulman GI. ",{"type":21,"tag":42,"props":1975,"children":1976},{},[1977],{"type":34,"value":1978},"The pathogenesis of insulin resistance.",{"type":34,"value":450},{"type":21,"tag":30,"props":1981,"children":1982},{},[1983],{"type":34,"value":1984},"J Clin Invest",{"type":34,"value":1842},{"type":21,"tag":91,"props":1987,"children":1989},{"href":884,"rel":1988},[169],[1990],{"type":34,"value":1779},{"type":21,"tag":148,"props":1992,"children":1993},{},[1994,1995,2000,2001,2006,2008],{"type":34,"value":1973},{"type":21,"tag":42,"props":1996,"children":1997},{},[1998],{"type":34,"value":1999},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":34,"value":450},{"type":21,"tag":30,"props":2002,"children":2003},{},[2004],{"type":34,"value":2005},"Cell Metabolism",{"type":34,"value":2007}," 2018. ",{"type":21,"tag":91,"props":2009,"children":2011},{"href":892,"rel":2010},[169],[2012],{"type":34,"value":1779},{"type":21,"tag":148,"props":2014,"children":2015},{},[2016,2018,2023,2024,2029,2030],{"type":34,"value":2017},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":21,"tag":42,"props":2019,"children":2020},{},[2021],{"type":34,"value":2022},"The multiple-hit pathogenesis of NAFLD.",{"type":34,"value":450},{"type":21,"tag":30,"props":2025,"children":2026},{},[2027],{"type":34,"value":2028},"Metabolism",{"type":34,"value":1842},{"type":21,"tag":91,"props":2031,"children":2033},{"href":857,"rel":2032},[169],[2034],{"type":34,"value":1629},{"type":21,"tag":148,"props":2036,"children":2037},{},[2038,2040,2045,2046,2050,2052],{"type":34,"value":2039},"Donnelly KL, et al. ",{"type":21,"tag":42,"props":2041,"children":2042},{},[2043],{"type":34,"value":2044},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":34,"value":450},{"type":21,"tag":30,"props":2047,"children":2048},{},[2049],{"type":34,"value":1984},{"type":34,"value":2051}," 2005. ",{"type":21,"tag":91,"props":2053,"children":2055},{"href":919,"rel":2054},[169],[2056],{"type":34,"value":1779},{"type":21,"tag":148,"props":2058,"children":2059},{},[2060,2062,2067,2068,2072,2073],{"type":34,"value":2061},"Locatelli JC, et al. ",{"type":21,"tag":42,"props":2063,"children":2064},{},[2065],{"type":34,"value":2066},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":34,"value":450},{"type":21,"tag":30,"props":2069,"children":2070},{},[2071],{"type":34,"value":1863},{"type":34,"value":1656},{"type":21,"tag":91,"props":2074,"children":2076},{"href":779,"rel":2075},[169],[2077],{"type":34,"value":2078},"Article",{"type":21,"tag":148,"props":2080,"children":2081},{},[2082,2084,2089,2090,2095,2097],{"type":34,"value":2083},"Koceva A, et al. ",{"type":21,"tag":42,"props":2085,"children":2086},{},[2087],{"type":34,"value":2088},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":34,"value":450},{"type":21,"tag":30,"props":2091,"children":2092},{},[2093],{"type":34,"value":2094},"Medicina",{"type":34,"value":2096}," 2025. ",{"type":21,"tag":91,"props":2098,"children":2100},{"href":311,"rel":2099},[169],[2101],{"type":34,"value":1779},{"type":21,"tag":148,"props":2103,"children":2104},{},[2105,2107,2112,2113,2118,2119],{"type":34,"value":2106},"Tinsley GM, et al. ",{"type":21,"tag":42,"props":2108,"children":2109},{},[2110],{"type":34,"value":2111},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":34,"value":450},{"type":21,"tag":30,"props":2114,"children":2115},{},[2116],{"type":34,"value":2117},"J Endocr Soc",{"type":34,"value":1656},{"type":21,"tag":91,"props":2120,"children":2122},{"href":770,"rel":2121},[169],[2123],{"type":34,"value":1779},{"type":21,"tag":148,"props":2125,"children":2126},{},[2127,2129,2134,2135,2140,2141],{"type":34,"value":2128},"do Nascimento TS, et al. ",{"type":21,"tag":42,"props":2130,"children":2131},{},[2132],{"type":34,"value":2133},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":34,"value":450},{"type":21,"tag":30,"props":2136,"children":2137},{},[2138],{"type":34,"value":2139},"Perioper Med",{"type":34,"value":1656},{"type":21,"tag":91,"props":2142,"children":2144},{"href":1384,"rel":2143},[169],[2145],{"type":34,"value":1779},{"type":21,"tag":148,"props":2147,"children":2148},{},[2149,2151,2156,2157,2162,2163],{"type":34,"value":2150},"Tan Y, et al. ",{"type":21,"tag":42,"props":2152,"children":2153},{},[2154],{"type":34,"value":2155},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":34,"value":450},{"type":21,"tag":30,"props":2158,"children":2159},{},[2160],{"type":34,"value":2161},"Dig Liver Dis",{"type":34,"value":2096},{"type":21,"tag":91,"props":2164,"children":2166},{"href":1392,"rel":2165},[169],[2167],{"type":34,"value":1629},{"type":21,"tag":148,"props":2169,"children":2170},{},[2171,2173,2178,2179,2184,2185],{"type":34,"value":2172},"Ushakumari DS, et al. ",{"type":21,"tag":42,"props":2174,"children":2175},{},[2176],{"type":34,"value":2177},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":34,"value":450},{"type":21,"tag":30,"props":2180,"children":2181},{},[2182],{"type":34,"value":2183},"Anesthesiology",{"type":34,"value":1656},{"type":21,"tag":91,"props":2186,"children":2188},{"href":1410,"rel":2187},[169],[2189],{"type":34,"value":1629},{"type":21,"tag":148,"props":2191,"children":2192},{},[2193,2195,2200,2201,2205,2206],{"type":34,"value":2194},"Jalleh RJ, et al. ",{"type":21,"tag":42,"props":2196,"children":2197},{},[2198],{"type":34,"value":2199},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":34,"value":450},{"type":21,"tag":30,"props":2202,"children":2203},{},[2204],{"type":34,"value":1795},{"type":34,"value":1656},{"type":21,"tag":91,"props":2207,"children":2209},{"href":1401,"rel":2208},[169],[2210],{"type":34,"value":1779},{"type":21,"tag":148,"props":2212,"children":2213},{},[2214,2216,2221,2222,2227,2228],{"type":34,"value":2215},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":21,"tag":42,"props":2217,"children":2218},{},[2219],{"type":34,"value":2220},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":34,"value":450},{"type":21,"tag":30,"props":2223,"children":2224},{},[2225],{"type":34,"value":2226},"JCI Insight",{"type":34,"value":2096},{"type":21,"tag":91,"props":2229,"children":2231},{"href":1519,"rel":2230},[169],[2232],{"type":34,"value":1629},{"type":21,"tag":148,"props":2234,"children":2235},{},[2236,2238,2243,2244,2248,2250],{"type":34,"value":2237},"Wilding JPH, et al. ",{"type":21,"tag":42,"props":2239,"children":2240},{},[2241],{"type":34,"value":2242},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":34,"value":450},{"type":21,"tag":30,"props":2245,"children":2246},{},[2247],{"type":34,"value":1621},{"type":34,"value":2249}," 2021. ",{"type":21,"tag":91,"props":2251,"children":2253},{"href":1032,"rel":2252},[169],[2254],{"type":34,"value":1629},{"type":21,"tag":148,"props":2256,"children":2257},{},[2258,2260,2265,2266,2270,2271],{"type":34,"value":2259},"Jastreboff AM, et al. ",{"type":21,"tag":42,"props":2261,"children":2262},{},[2263],{"type":34,"value":2264},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":34,"value":450},{"type":21,"tag":30,"props":2267,"children":2268},{},[2269],{"type":34,"value":1621},{"type":34,"value":1773},{"type":21,"tag":91,"props":2272,"children":2274},{"href":1047,"rel":2273},[169],[2275],{"type":34,"value":1629},{"type":21,"tag":148,"props":2277,"children":2278},{},[2279,2281,2286,2287,2292,2293],{"type":34,"value":2280},"Holst JJ. ",{"type":21,"tag":42,"props":2282,"children":2283},{},[2284],{"type":34,"value":2285},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":34,"value":450},{"type":21,"tag":30,"props":2288,"children":2289},{},[2290],{"type":34,"value":2291},"Nature Metabolism",{"type":34,"value":1656},{"type":21,"tag":91,"props":2294,"children":2296},{"href":1056,"rel":2295},[169],[2297],{"type":34,"value":1629},{"type":21,"tag":148,"props":2299,"children":2300},{},[2301,2303,2308,2309,2314,2315],{"type":34,"value":2302},"Nauck MA, et al. ",{"type":21,"tag":42,"props":2304,"children":2305},{},[2306],{"type":34,"value":2307},"The evolving story of incretins (GIP and GLP-1).",{"type":34,"value":450},{"type":21,"tag":30,"props":2310,"children":2311},{},[2312],{"type":34,"value":2313},"Diabetes Obes Metab",{"type":34,"value":2249},{"type":21,"tag":91,"props":2316,"children":2318},{"href":1064,"rel":2317},[169],[2319],{"type":34,"value":2078},{"type":21,"tag":148,"props":2321,"children":2322},{},[2323,2325,2330,2332],{"type":34,"value":2324},"California Board of Chiropractic Examiners. ",{"type":21,"tag":42,"props":2326,"children":2327},{},[2328],{"type":34,"value":2329},"Meeting materials, 29 Oct 2020",{"type":34,"value":2331}," (licence DC 29377, revoked 8 Jul 2020). ",{"type":21,"tag":91,"props":2333,"children":2335},{"href":167,"rel":2334},[169],[2336],{"type":34,"value":2337},"PDF",{"type":21,"tag":148,"props":2339,"children":2340},{},[2341,2342,2347,2348],{"type":34,"value":2324},{"type":21,"tag":42,"props":2343,"children":2344},{},[2345],{"type":34,"value":2346},"Final Disciplinary Actions.",{"type":34,"value":450},{"type":21,"tag":91,"props":2349,"children":2351},{"href":384,"rel":2350},[169],[2352],{"type":34,"value":2353},"Page",{"type":21,"tag":148,"props":2355,"children":2356},{},[2357,2359,2364,2365],{"type":34,"value":2358},"California Department of Consumer Affairs. ",{"type":21,"tag":42,"props":2360,"children":2361},{},[2362],{"type":34,"value":2363},"License Search.",{"type":34,"value":450},{"type":21,"tag":91,"props":2366,"children":2368},{"href":393,"rel":2367},[169],[2369],{"type":34,"value":2370},"Lookup",{"type":21,"tag":148,"props":2372,"children":2373},{},[2374,2376,2381,2382],{"type":34,"value":2375},"EliteBiogenix. ",{"type":21,"tag":42,"props":2377,"children":2378},{},[2379],{"type":34,"value":2380},"Research peptides and SARMs vendor (in-vitro research only).",{"type":34,"value":450},{"type":21,"tag":91,"props":2383,"children":2385},{"href":177,"rel":2384},[169],[2386],{"type":34,"value":2387},"Site",{"type":21,"tag":148,"props":2389,"children":2390},{},[2391,2393,2398,2399,2404,2405],{"type":34,"value":2392},"Bachmeyer T. ",{"type":21,"tag":42,"props":2394,"children":2395},{},[2396],{"type":34,"value":2397},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":34,"value":450},{"type":21,"tag":30,"props":2400,"children":2401},{},[2402],{"type":34,"value":2403},"YouTube.",{"type":34,"value":450},{"type":21,"tag":91,"props":2406,"children":2409},{"href":2407,"rel":2408},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[169],[2410],{"type":34,"value":2411},"Video",{"title":7,"searchDepth":2413,"depth":2413,"links":2414},2,[2415,2416,2417,2418,2419,2420,2421,2422,2423,2424,2425,2426,2427,2428,2429,2430,2431,2432,2433],{"id":127,"depth":2413,"text":130},{"id":331,"depth":2413,"text":334},{"id":421,"depth":2413,"text":424},{"id":483,"depth":2413,"text":486},{"id":564,"depth":2413,"text":567},{"id":668,"depth":2413,"text":671},{"id":734,"depth":2413,"text":737},{"id":788,"depth":2413,"text":791},{"id":808,"depth":2413,"text":811},{"id":819,"depth":2413,"text":822},{"id":873,"depth":2413,"text":876},{"id":935,"depth":2413,"text":938},{"id":1014,"depth":2413,"text":1017},{"id":1354,"depth":2413,"text":1357},{"id":1425,"depth":2413,"text":1428},{"id":1470,"depth":2413,"text":1473},{"id":1508,"depth":2413,"text":1511},{"id":1528,"depth":2413,"text":1531},{"id":1598,"depth":2413,"text":1601},"markdown","content:blog:de:retatrutide-liver-damage-myths.md","content","blog\u002Fde\u002Fretatrutide-liver-damage-myths.md","blog\u002Fde\u002Fretatrutide-liver-damage-myths","md"]